The U.S. compounding pharmacy market was valued at $6.31 billion in 2024 and is projected to reach $10.76 billion by 2033, driven by drug shortage volume and demand for personalized therapies.
A 503A pharmacy and a 503B outsourcing facility operate under fundamentally different legal frameworks. The 503A model relies on state board oversight and USP standards; the 503B model is subject to FDA’s Current Good Manufacturing Practice (CGMP) regulations under 21 CFR Parts 210 and 211. The strategic choice between them determines market access, scalable capacity, and litigation exposure.
FDA compliance under the drug shortage exception does not confer immunity from patent infringement claims. The Patent Act contains no shortage carve-out. Eli Lilly and Novo Nordisk have both initiated infringement actions against compounders producing GLP-1 agonists during active FDA-declared shortages.
Blockbuster drugs are rarely protected by a single patent. AbbVie’s Humira carries an estimated 130 granted U.S. patents with a projected patent life of 39 years, illustrating the scale of the thicket problem. Compounders who analyze only the primary composition-of-matter patent will miss most of the legal exposure.
A Freedom-to-Operate (FTO) analysis is not optional. It is a pre-launch legal prerequisite for any new compounded formulation. The average cost of patent litigation through trial exceeded $3 million in 2023; FTO counsel costs a fraction of that.
Biological products licensed under the Public Health Service (PHS) Act are categorically ineligible for the 503A and 503B compounding exemptions as of March 23, 2020. Compounders cannot formulate drugs like Humira or Keytruda from bulk drug substances, shortage or not.
Part 1: The Compounding Regulatory Architecture
The Market Context
The U.S. compounding pharmacy sector is not a niche service business. It is a $6.31 billion industry (2024) on a trajectory to $10.76 billion by 2033, growing at a CAGR of 6.1%. The global compounding market is larger still, projected to reach $33.73 billion by 2034. These figures reflect two structural forces: persistent commercial drug shortages and measurable clinical demand for formulations that approved drug products cannot satisfy.
For IP teams and portfolio managers, this growth is not simply a pharmacy story. It is an indicator of where regulatory white space and patent pressure interact. Every dollar of compounding market growth represents a challenge to an innovator’s revenue protection strategy, a litigation target for brand manufacturers, and a potential source of liability for compounders who have not done their patent homework.
The Regulatory Genesis: Why DQSA Created Two Distinct Legal Universes
The Drug Quality and Security Act (DQSA), signed in 2013, was Congress’s direct response to the 2012 New England Compounding Center fungal meningitis outbreak that killed more than 60 people. NECC was functioning as a de facto large-scale manufacturer while operating under state pharmacy board oversight, a regulatory arbitrage that cost lives. The DQSA closed that gap by establishing the current two-tier system: the 503A compounding pharmacy and the 503B outsourcing facility.
Understanding how these two designations operate is prerequisite knowledge for any patent strategy discussion, because they determine the legal space in which compounded products exist, who can access them, and at what scale.
503A Compounding Pharmacies: Operational Architecture and Strategic Limits
The Defining Legal Characteristics
A 503A pharmacy prepares compounded drug products exclusively upon receipt of a valid prescription for an identified individual patient. This patient-specificity requirement is not a procedural formality; it is the structural boundary that separates 503A pharmacies from regulated manufacturers. Compounding in anticipation of prescriptions, at volume, is prohibited.
503A facilities are regulated primarily by state boards of pharmacy and must comply with USP General Chapter 795 (non-sterile preparations) and USP General Chapter 797 (sterile preparations). They are not required to register with the FDA, though the agency retains inspection authority when risk is identified.
Critically, 503A pharmacies are exempt from CGMP requirements under 21 CFR Parts 210 and 211, provided all statutory conditions are satisfied. This exemption reduces capital barriers to entry but carries a corresponding quality risk acknowledgment: the FDA’s own position is that compounded drugs, absent CGMP oversight, carry inherently higher quality risks than approved drug products.
IP Valuation Dimension: The 503A Business Model’s Patent Exposure
From an IP and portfolio perspective, the 503A model’s core vulnerability is structural. Because 503A pharmacies rely on the ‘significant difference’ exception to justify compounding formulations that resemble commercial products, each prescription-level transaction is also a potential infringement event. A 503A pharmacy producing a modified version of a brand-name formulation is exercising a right that the FDA’s ‘essentially a copy’ doctrine conditionally permits, but that the Patent Act does not address.
This means that for any 503A pharmacy with ambitions beyond straightforward patient-specific customization (flavor changes, dye removal, dosage form alteration), the relevant IP question is: does the requested modification steer the formulation outside the claims of the brand’s formulation patents, method-of-use patents, and polymorph patents? That question requires patent claim mapping, not just a prescription check.
Key Takeaways: 503A
The patient-specific prescription requirement is a hard legal ceiling on 503A production scale. Any operation that exceeds it risks FDA reclassification as an unlicensed manufacturer.
The CGMP exemption lowers capital costs but creates quality risk that institutional buyers, particularly hospitals, recognize and penalize in procurement decisions.
The four-prescriptions-per-month FDA enforcement threshold for compounding ‘essentially copies’ is not a safe harbor; it is a de minimis enforcement posture that can shift without notice.
Every compounded formulation that resembles a patented commercial product warrants a patent claim analysis, regardless of the FDA-permissibility of the clinical modification.
503B Outsourcing Facilities: Scale, CGMP, and a Different Risk Profile
The Defining Legal Characteristics
503B outsourcing facilities are the DQSA’s attempt to legitimize large-scale compounding under direct FDA oversight. They can produce compounded drugs in large batches without patient-specific prescriptions and distribute to healthcare facilities, hospitals, ambulatory surgery centers, and physician offices for ‘office use.’ They must register with the FDA, submit semi-annual product reports, and comply in full with CGMP requirements.
The CGMP mandate is operationally demanding. It requires process validation for every manufacturing operation, batch release testing for potency and sterility, independent quality control authority, and environmental monitoring on a per-production-shift basis in critical cleanroom areas. These requirements impose capital costs in the millions of dollars to establish and maintain a compliant facility.
IP Valuation Dimension: The 503B Facility as a Quasi-Manufacturer
The 503B designation effectively creates a class of entities that occupy the legal and economic position of pharmaceutical manufacturers without holding approved drug applications. From an IP valuation standpoint, the assets of a 503B facility are concentrated in three areas: the CGMP-compliant manufacturing infrastructure (which is difficult and expensive to replicate), proprietary formulation know-how (which may itself be patentable), and customer relationships with health systems.
The formulation know-how asset deserves specific attention. When a 503B facility develops a stable, novel compounded formulation, that formulation may qualify for patent protection as a new composition or process, independent of whether it resembles a commercial product. 503B operators who invest in formulation R&D but do not systematically evaluate and protect that IP are leaving significant asset value uncaptured.
The Stricter ‘Essentially a Copy’ Standard for 503B Facilities
The ‘essentially a copy’ prohibition is more absolute for 503B facilities than for 503A pharmacies. For 503B operators, the rule applies in two tiers.
First, if a compounded drug is ‘identical or nearly identical’ to an approved drug — meaning same API, same route of administration, same dosage form, same strength, and same excipients — compounding is categorically prohibited. No clinical difference exception applies. This is a hard stop that precludes any 503B facility from producing a product that is analytically indistinguishable from an approved drug, unless that drug is on the FDA shortage list.
Second, if a compounded drug contains the same API but differs in at least one material parameter (different excipient, different concentration), it is still considered an ‘essentially a copy’ unless a practitioner certifies that the change produces a ‘clinical difference’ for a defined patient population. This certification must be documented on a non-patient-specific order and must be retained by the facility.
The operational implication: 503B facilities must maintain an active, documented clinical differentiation file for every compounded product that shares an API with an approved drug. This is not merely a compliance exercise; it is the primary legal defense against both FDA enforcement and patent infringement claims premised on market substitution.
Key Takeaways: 503B
CGMP compliance is the 503B’s primary competitive asset and its highest operational cost. Facilities that achieve reliable CGMP compliance earn access to the hospital and health system market; those that fail inspections lose it quickly and publicly.
The ‘identical or nearly identical’ standard creates a formulation design constraint that should be built into every 503B product development workflow before any manufacturing investment is made.
Proprietary compounded formulations developed in-house may qualify for patent protection. Systematic IP capture through provisional patent applications should accompany formulation development cycles.
503B operators entering the shortage market must build a patent risk assessment into their standard operating procedure for shortage product selection, not just a regulatory review.
The 503A/503B Symbiosis: Opportunity and Legal Fragility
A 503A pharmacy can contract with a 503B facility to source CGMP-compliant compounded sterile products that it cannot produce at the required quality standard. This model provides the 503A with access to more complex therapies without the capital investment required to build a compliant cleanroom, and gives the 503B an additional distribution channel into the patient-facing market.
The legal foundation of this arrangement is narrower than most practitioners assume. Section 503B(a)(8) of the FD&C Act restricts the sale or transfer of compounded drugs by any entity other than the producing outsourcing facility. FDA guidance clarifies that a 503B may sell directly to a 503A for dispensing pursuant to a patient-specific prescription. But this interpretation is guidance, not statute, and is subject to revision.
Liability allocation in these arrangements is also unresolved by statute. If a patient is harmed by a product manufactured by a 503B but dispensed by a 503A, both entities face exposure. The dispensing pharmacist’s duty of care is not delegable to the manufacturer. Any 503A entering a 503B supply relationship must conduct technical due diligence on the partner’s inspection history, batch release records, and recall procedures, and must execute a written quality agreement that explicitly addresses recall procedures, adverse event reporting obligations, and indemnification terms.
Part 2: The Patent Architecture Surrounding Compounded Drugs
How the U.S. Patent System Works Against Compounders
The Foundational Mechanics of Pharmaceutical Patents
A U.S. patent grants the owner the right to exclude others from making, using, selling, or importing the patented invention for 20 years from the filing date. It does not grant the owner the right to practice the invention, which may require licenses to earlier patents. The right to exclude is a right to litigate, which is why the financial resources of the patent holder matter as much as the merits of the patent itself.
To be granted, a patent must satisfy three criteria: usefulness, novelty, and non-obviousness. Of these, non-obviousness is the most contested in pharmaceutical litigation. A formulation that improves bioavailability through a known polymer will face serious obviousness challenges from a generic filer asserting Paragraph IV certification, but that same challenge costs millions of dollars to sustain through trial, a cost most compounders cannot bear.
The Five Patent Categories That Enclose a Branded Drug
Innovator companies do not rely on a single patent. They build layered IP portfolios. For a compounder, the relevant categories of pharmaceutical patents are:
Composition-of-matter patents protect the API molecule itself. These are the broadest patents in a portfolio, typically filed earliest, and therefore usually the first to expire. Their expiration is the event that opens the ANDA pathway for generic manufacturers. But for compounders, API patent expiry does not resolve the formulation and method-of-use patent exposure that sits on top of it.
Formulation patents protect the specific combination of API with excipients. These are the patents most directly relevant to compounders, who are in the business of formulating. A formulation patent may claim a specific polymer concentration range, a pH window, a particle size distribution, or a combination of stabilizers that together achieve the required shelf life or dissolution profile. These patents are frequently filed years after the original NDA approval, are often not subject to the same obviousness challenges as composition patents, and can extend effective market exclusivity by a decade or more.
Method-of-use patents protect a specific indication or dosing regimen. A method-of-use patent does not prevent compounding the drug per se, but it exposes anyone who induces use of the compounded drug for the patented indication, including the prescribing physician and potentially the dispensing pharmacy, to induced infringement claims.
Polymorph patents protect specific crystalline forms of an API that exhibit different solubility, stability, or bioavailability characteristics. Many APIs exist in multiple crystalline forms, and the commercially approved form may be covered by a polymorph patent even after the original composition patent expires.
Delivery device patents protect the physical mechanism of administration: auto-injectors, prefilled syringes, metered-dose inhalers, nasal spray pumps. These are particularly relevant in the GLP-1 and biologic context, where the injection device is often as tightly protected as the drug itself. The FTC has taken the position that certain device patents listed in the Orange Book by brand manufacturers are improper listings that unfairly block generic and biosimilar competition, and has formally challenged several such listings.
FDA Exclusivity vs. Patents: A Distinction That Creates Compounding Windows
Patents are issued by the USPTO. Exclusivity is granted by the FDA upon NDA approval. These are separate legal protections that may run concurrently, sequentially, or independently.
FDA exclusivity periods:
New Chemical Entity (NCE) exclusivity: 5 years from NDA approval, blocks ANDA filings during this period.
Orphan Drug Exclusivity (ODE): 7 years for drugs treating diseases affecting fewer than 200,000 U.S. patients, blocks approval of same drug for same indication.
New Clinical Investigation exclusivity: 3 years for an approved change supported by new clinical investigations.
Pediatric exclusivity: 6 months added to existing patents and exclusivity when the manufacturer completes FDA-requested pediatric studies.
The strategic relevance for compounders: if a drug’s primary composition-of-matter patent has expired but 3-year new clinical investigation exclusivity is still in effect for a reformulation, the ANDA pathway is blocked for generics, but the FDA’s ‘essentially a copy’ doctrine may still permit compounding of the original formulation for patients with a documented clinical need. This creates a narrow compounding window in the interval between primary patent expiry and generic market entry, provided the compounder has done formulation patent analysis.
The Hatch-Waxman Framework: Why Generic Market Dynamics Matter to Compounders
The Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, created the ANDA pathway that allows generic companies to rely on an innovator’s safety and efficacy data, provided they demonstrate bioequivalence and either certify that no relevant patents exist (Paragraph I or II certification) or certify that relevant patents are invalid or not infringed (Paragraph IV certification).
Paragraph IV filings are the pharmaceutical industry’s primary mechanism for patent challenge. When a generic company files a Paragraph IV certification against a specific Orange Book-listed patent, the brand manufacturer has 45 days to file a patent infringement suit. If it does, a 30-month automatic stay blocks FDA approval of the ANDA while litigation proceeds. For compounders, Paragraph IV activity is commercially valuable intelligence: a filed challenge signals that the generic industry believes a specific patent is vulnerable. High Paragraph IV activity against a particular patent in a drug’s Orange Book listing is a marker that experienced compounders and their counsel use to assess the patent’s strength before committing to formulation development.
The Orange Book: Reading the Battleground Map
The Orange Book (formally, ‘Approved Drug Products with Therapeutic Equivalence Evaluations’) is the FDA’s registry of patents and exclusivities asserted by NDA holders. Under Hatch-Waxman, an NDA applicant must list patents covering the drug substance, drug product, and approved methods of use. Process patents and packaging patents are not eligible for listing.
The FDA does not verify the accuracy or validity of listed patents. It publishes what manufacturers submit. This has led to well-documented disputes over improper listings, particularly for delivery device patents, and explains why the FTC’s current enforcement initiative targeting Orange Book patent challenges is significant for the compounding sector.
The practical procedure for Orange Book review:
Access the Electronic Orange Book via FDA.gov.
Search by brand name or active ingredient.
Select the specific NDA application number.
Navigate to ‘Patent and Exclusivity Information.’
Document every listed patent number, expiration date, and the patent type (drug substance, drug product, or method of use).
This list is your starting document for an FTO analysis. It is not your ending document.
IP Valuation: The Innovator’s Patent Portfolio as a Revenue Protection Mechanism
Evergreening: The Technology Roadmap Innovators Use to Extend Exclusivity
Evergreening is the systematic use of lifecycle management patents to maintain revenue streams beyond the expiration of primary composition-of-matter protection. It is not a single tactic; it is a structured IP strategy with a defined technology roadmap.
The standard evergreening sequence for a small-molecule drug follows a recognizable pattern. The original composition-of-matter patent is filed at the time of compound discovery, typically 10 to 15 years before commercial approval, which means effective remaining patent life at launch is often 7 to 10 years. During this exclusivity window, the lifecycle management team begins systematic protection of secondary IP.
The most common evergreening tactics, in order of IP filing sequence:
Controlled-release formulation development begins 4 to 7 years after NDA approval. The manufacturer patents a new delivery system, typically extended-release or modified-release, that allows once-daily dosing. Patient compliance benefits are documented in clinical trials that simultaneously generate 3-year new clinical investigation exclusivity. The immediate-release formulation is then often discontinued or de-emphasized, even if clinically equivalent, forcing patients and prescribers toward the reformulated, re-protected product.
Chiral switching involves isolating and patenting the active enantiomer from a racemic mixture sold under the original patent. Esomeprazole (Nexium) from omeprazole (Prilosec) is the canonical example. The single enantiomer may have a modestly improved tolerability profile, but the primary value is the fresh 20-year patent term on the new molecule, which blocks generic substitution of the enantiomer-specific product even as generics enter the racemic market.
Fixed-dose combination products pair the primary API with a complementary agent (a co-drug, a bioavailability enhancer, or a pharmacokinetic modifier) and patent the combination. The combination product may offer genuine clinical benefit, but it also resets the IP clock and makes therapeutic substitution with individual generic components clinically awkward.
Polymorph patents protect crystalline forms that emerge from formulation development programs. APIs frequently exist in multiple polymorphic forms with different solubility and stability characteristics. Filing patents on the specific polymorph used in the approved formulation, and potentially on competing polymorphs as well, creates a barrier to generic entry even after the original API patent expires, because the generic must use a non-infringing polymorph that may be harder to manufacture or less stable.
Pediatric formulation patents emerge from FDA-requested pediatric studies. Beyond the 6-month pediatric exclusivity added to existing IP, the pediatric formulation itself (a liquid suspension, a chewable tablet, or a sprinkle capsule) may be independently patentable, creating protection for a high-value patient population.
IP Valuation Application: Humira as a Case Study in Patent Thicket Construction
AbbVie’s adalimumab (Humira) is the most studied example of patent thicket construction in the pharmaceutical industry. The drug achieved first approval in 2002. By the time biosimilar competition finally entered the U.S. market in 2023 following settlement of litigation, AbbVie had filed an estimated 239 patent applications and obtained approximately 130 granted U.S. patents. Roughly 90% of those patents were filed after the drug was already approved.
The financial consequence: analysts estimate that Humira’s patent thicket was responsible for approximately $7.6 billion in delayed biosimilar savings in a single year. The five-drug patent thicket analysis conducted for congressional reference identified $16 billion in total annual healthcare system cost attributable to thicket-driven delays across a small set of drugs.
For compounders, Humira is not a directly relevant target because adalimumab is a biologic licensed under the PHS Act and therefore categorically ineligible for 503A/503B compounding. Its strategic relevance is architectural: the same approach AbbVie used with Humira, layering dozens of formulation, device, and method-of-use patents over a composition-of-matter foundation, is used by manufacturers of the small-molecule drugs that compounders do encounter. Any blockbuster small-molecule drug approved in the last 15 years should be assumed to have a patent thicket until comprehensive Orange Book and USPTO analysis demonstrates otherwise.
Investment Strategy Note for Portfolio Managers
For institutional investors evaluating compounding sector companies, the patent thicket problem has direct valuation implications. A 503B facility whose product mix is concentrated in one or two shortage drugs faces a specific risk: when those shortage designations are lifted, both the FDA regulatory permission and any implied market immunity dissolve simultaneously. The facility is then exposed to patent enforcement from manufacturers who spent the shortage period documenting the compounder’s market intrusion. Revenue multiples applied to shortage-dependent product lines should be discounted to reflect this binary risk event.
Portfolio positions in compounding sector operators should be assessed for: (1) product concentration in shortage-derived revenue, (2) the strength of the operator’s documented FTO analysis for each shortage product, (3) pending litigation exposure from brand manufacturers, and (4) the depth of the operator’s proprietary non-shortage formulation pipeline, which represents defensible, durable revenue.
Key Takeaways: Patent Architecture
Composition-of-matter patents are the first to expire; formulation, polymorph, and method-of-use patents are the last. Compounders who focus only on primary API patent expiry are analyzing the wrong layer of the stack.
Evergreening follows a predictable roadmap. Knowing a drug’s NDA approval date, its primary patent expiry, and its secondary patent filing dates allows a competent IP analyst to map the full exclusivity runway.
The FTC’s ongoing Orange Book patent challenge campaign may result in some device and formulation patents being delisted. Compounders and their counsel should monitor FTC docket filings against patents in their target drug categories.
Paragraph IV filing history is free, publicly available competitive intelligence. High challenge volume against a specific patent is a signal of perceived weakness worth investigating before committing to a design-around program.
Part 3: Where FDA Compounding Law and Patent Law Collide
The ‘Essentially a Copy’ Doctrine: Operational Rules and Strategic Exceptions
The Two-Pronged Test for 503A Pharmacies
The FDA’s ‘essentially a copy’ prohibition applies to 503A facilities only when two conditions are simultaneously present: (1) the compounded drug is substantially similar to a commercially available drug product, and (2) the pharmacy compounds it regularly or in inordinate amounts. Both prongs must be satisfied for an FDA violation.
The FDA defines substantial similarity using a three-part functional test. A compounded drug is substantially similar if it contains the same API, the same or similar dosage strength (within 10% of the commercial product’s strength, or easily substitutable through unit adjustment), and uses the same route of administration.
The ‘significant difference’ exception is the primary operating mechanism for 503A pharmacies engaged in legitimate customization. A compounded drug is not considered a copy if the prescribing practitioner has determined and documented on the prescription that a change from the commercial product produces a significant difference for that specific identified patient. The change must be clinically meaningful: altering the dosage form because the patient cannot swallow tablets qualifies; compounding because the compound is cheaper does not.
The FDA has indicated, through enforcement policy guidance, that it generally does not intend to take action against a pharmacy for compounding a commercially available drug when it fills four or fewer prescriptions of that formulation in a single calendar month. This threshold is not a statutory safe harbor; it is a prosecutorial discretion standard that can be revised.
The Stricter 503B Standard: Clinical Difference Documentation
For 503B facilities, the ‘essentially a copy’ prohibition is unconditional for products meeting the ‘identical or nearly identical’ standard. Compounding is prohibited regardless of volume or clinical justification when the compounded product shares the API, route, dosage form, strength, and excipients with an approved drug. The only exception is an active FDA shortage listing.
For 503B products that differ from an approved drug in at least one material parameter (a different excipient or a different strength), the clinical difference exception applies. The facility must obtain a practitioner statement identifying the specific change and affirming that it produces a clinical difference for the patient population served. This statement must accompany non-patient-specific orders and be retained as part of the batch record.
The strategic implication for 503B product development teams: clinical differentiation must be defined and documented before the product enters commercial production, not retrospectively when FDA inquires. Formulation scientists should work alongside regulatory and legal counsel during product development to construct the clinical differentiation file in real time.
The Drug Shortage Exception: Revenue Opportunity with Binary Risk
How the Shortage Designation Works
When the FDA places a drug on its official shortage list maintained under Section 506E of the FD&C Act, it removes the drug from the category of ‘commercially available’ for compounding purposes. Both 503A and 503B facilities may then compound versions of the drug without triggering the ‘essentially a copy’ prohibition. This is the primary regulatory mechanism that allows compounders to serve as a production backstop during supply disruptions.
FDA shortage designations can be lifted with limited advance notice. When a shortage is resolved:
503A facilities must cease compounding the previously shortage-listed drug immediately.
503B facilities receive a 60-day wind-down period to fulfill existing orders before ceasing production.
The 60-day wind-down is a meaningful operational buffer but not a financial one. A 503B facility that has scaled manufacturing infrastructure, hired specialized staff, and established customer relationships around a shortage product faces significant sunk costs when the shortage designation is lifted.
Case Study: GLP-1 Agonists — The Patent-FDA Compliance Collision
The GLP-1 agonist market produced the clearest real-world demonstration of the patent-FDA compliance trap. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were placed on the FDA shortage list in 2022 as Novo Nordisk and Eli Lilly could not scale production to meet demand driven by the drugs’ effectiveness in type 2 diabetes and obesity management.
The shortage designation triggered immediate compounding activity across the 503A and 503B sectors. An ecosystem of telehealth platforms, weight-loss clinics, and medical spas grew rapidly around access to compounded semaglutide and tirzepatide, which were available at materially lower prices than the branded products.
Novo Nordisk and Eli Lilly did not wait for the FDA to resolve the shortage. Both companies filed patent infringement suits against compounding pharmacies, medical spas, and telehealth operators producing or selling compounded versions of their drugs. The suits alleged patent infringement under the Patent Act, trademark infringement for use of brand names including ‘Ozempic,’ ‘Wegovy,’ ‘Mounjaro,’ and ‘Zepbound’ in marketing materials, and false advertising for language implying that compounded versions were FDA-approved or therapeutically equivalent to the branded products.
When the FDA subsequently delisted tirzepatide from the shortage list, a trade group representing compounding facilities filed suit against the FDA, arguing the delisting decision was arbitrary and capricious. Eli Lilly intervened to defend the FDA’s position. The litigation illustrated the full cycle: a shortage creates a market, compounders enter under FDA permission, the manufacturer pursues patent enforcement during the shortage, the shortage ends and the 60-day wind-down begins, and legal disputes continue on multiple fronts simultaneously.
The Core Legal Paradox: FDA Compliance Is Not a Patent Shield
This point warrants explicit statement because misunderstanding it has produced catastrophic outcomes for compounding businesses.
The FDA’s shortage exception is a provision of the Federal Food, Drug, and Cosmetic Act. When a drug is on the shortage list, compounding a version of it does not violate the FD&C Act’s ‘essentially a copy’ prohibition. That is the full extent of the protection.
The U.S. Patent Act contains no shortage exception. It does not provide that compounding a patented drug during a declared shortage is permissible. It does not provide that FDA authorization to compound a drug functions as a license to the relevant patents. These are independent statutes administered by different agencies with different statutory mandates.
A brand manufacturer holding valid patents on a shortage-listed drug retains the full right to sue a compounder for patent infringement during the shortage period. The FDA’s permissive stance creates no affirmative defense to patent infringement claims. The two legal regimes operate in parallel and do not interact.
Compounders who decide to enter shortage markets must treat it as a calculated dual-risk decision: regulatory risk (the shortage could be lifted, triggering an immediate cessation requirement) and patent risk (the manufacturer may sue, regardless of shortage status). Both require advance analysis and mitigation strategies.
Key Takeaways: FDA/Patent Collision
FDA shortage designation and patent infringement exposure are legally independent. An FDA green light is not a patent license.
The 60-day wind-down for 503B facilities is an operational transition period, not a financial one. Business models built on single shortage drugs require structural revenue diversification before the designation is at risk of being lifted.
Trademark infringement is a separate, often more straightforward claim than patent infringement. Any marketing that uses a brand name or implies FDA equivalence is an independent source of litigation exposure, regardless of patent status.
The GLP-1 litigation wave produced detailed public records on how Novo Nordisk and Eli Lilly pursue infringement enforcement. These records are available through federal court dockets and are valuable competitive intelligence for any compounder evaluating entry into a shortage market controlled by a patent-holding manufacturer.
Part 4: Patent Intelligence — Tools, Tradecraft, and the Design-Around
Building a Patent Intelligence Operation
The Free Intelligence Layer: USPTO and Orange Book
The USPTO Patent Public Search system provides full-text access to all U.S. patents and published applications. An effective search strategy for a specific drug target should combine:
Assignee searches for the brand manufacturer and its parent companies, capturing the full corporate portfolio rather than only patents filed under the NDA holder’s name.
Chemical name and CAS number searches for the API and its known metabolites, pro-drugs, and salts.
Patent classification searches using the Cooperative Patent Classification (CPC) codes relevant to pharmaceutical formulations (A61K for preparations for medical purposes; A61K 9 for dosage forms; A61K 47 for excipients).
Cross-reference searches using cited patents within key patents already identified, which frequently uncovers the inventor’s earlier foundational filings.
Orange Book review identifies which patents the manufacturer considers commercially relevant enough to defend. The list of Orange Book patents should be cross-referenced against the USPTO’s full patent database for the same assignee to identify related patents that were not listed, either because they cover manufacturing processes (which are not Orange Book-eligible) or because the manufacturer chose not to list them while retaining infringement rights.
Commercial Intelligence Platforms: DrugPatentWatch as the Integration Layer
Government databases provide raw data. Commercial platforms provide analysis. DrugPatentWatch integrates Orange Book patent data with FDA regulatory records, ongoing litigation tracking, API supplier information, and global patent data across more than 130 countries. For a compounding pharmacy operating in a shortage market or developing a design-around program, this integration is material.
The specific features relevant to compounders and their IP counsel:
Litigation tracking: DrugPatentWatch monitors Paragraph IV certification filings, the 30-month stay initiation, trial outcomes, and settlement terms. When a generic company settles a Paragraph IV challenge and agrees to a specific authorized generic launch date, that settlement date is publicly reported. It reveals the brand manufacturer’s own assessment of patent strength and litigation risk, expressed in financial terms (the royalty rate or launch date concession). This is the most reliable signal available of how aggressively the manufacturer is likely to defend those patents against a compounder.
Formulation intelligence: The platform’s formulation detail database allows practitioners to review excipient combinations disclosed in patents and compare them to what was actually commercialized. Disclosures in the patent specification that were not included in the claims are prime candidates for design-around exploration.
Supplier intelligence: For any compounding operation, sourcing a non-infringing API from an FDA-registered bulk drug substance supplier is a prerequisite. DrugPatentWatch’s supplier database links patent data to API vendors, providing a starting list of sources whose manufacturing processes have not triggered infringement claims.
Loss of Exclusivity (LOE) forecasting: The platform’s LOE calendar identifies upcoming patent expirations and exclusivity end dates across the commercial drug portfolio. For a compounding pharmacy operating a proactive product development program, LOE forecasting allows 12 to 24 months of lead time for FTO analysis and formulation development before a market opening materializes.
Global patent tracking: Relevant prior art from other jurisdictions is frequently available in non-U.S. patent filings. European Patent Office (EPO) applications disclose prior art searches and examiner objections that have been used in USPTO proceedings to challenge U.S. patent validity. Accessing this data through a platform like DrugPatentWatch is faster and more systematic than navigating each jurisdiction’s database independently.
Design-Around Strategy: A Technical and Legal Playbook
Phase 1: Patent Deconstruction
The design-around process begins with forensic patent analysis. The objective is to identify not just what the patent claims, but why the inventor made the specific formulation choices reflected in the claims. This requires reading all sections of the patent in sequence.
The Background section establishes the problem the inventor was solving. Statements about prior art deficiencies (‘poor aqueous solubility,’ ‘chemical instability at physiological pH,’ ‘insufficient bioavailability in the fasted state’) define the technical challenge that the compounder’s alternative formulation must also address. Understanding the problem is as important as understanding the solution.
The Detailed Description section lists the full range of materials and methods the inventors considered. This section frequently enumerates dozens of potential excipients, concentration ranges, and process variations that were explored but not ultimately included in the claims. These disclosed-but-unclaimed elements are valuable. The doctrine of prosecution history estoppel generally limits a patent holder’s ability to claim, under the Doctrine of Equivalents, any element that was disclosed but not claimed, particularly if the amendment was made to overcome a prior art rejection.
The Claims section defines the exact legal boundary of the patent. The independent claims set the outer perimeter; the dependent claims narrow it with specific preferred embodiments. The language in claims is parsed with precision: ‘comprising’ means the listed elements are present but others may also be present; ‘consisting of’ means only the listed elements are present. A formulation that adds an element not listed in a ‘comprising’ claim does not thereby avoid infringement; a formulation that changes one element in a ‘consisting of’ claim may. A compounder working with patent claims must understand this language, or retain counsel who does.
The Examples section provides validated, real-world formulation data: specific weight percentages, dissolution profiles, stability data at accelerated conditions, comparative data against prior art formulations. These examples establish the quantitative targets the compounder’s design-around formulation must meet to demonstrate clinical equivalence.
Formulation Patent Deconstruction Reference Table
Patent Section
Key Analytical Question
Design-Around Value
Background
What problem did the inventor solve? What were the documented failures of prior formulations?
Identifies technical constraints your formulation must also satisfy; failure to address these will produce a non-equivalent product.
Detailed Description
What excipients, polymers, and process steps were disclosed but not claimed?
The unclaimed disclosure is your design-around materials list. Elements disclosed but not claimed are typically outside the Doctrine of Equivalents for that patent.
Claims (Independent)
What is the minimum set of elements required to infringe? What transitional phrase is used (‘comprising’ vs. ‘consisting of’)?
Defines the exact boundary you must design around. Every element of the claim must be mapped to your formulation.
Claims (Dependent)
What are the preferred embodiments? What concentration ranges are explicitly protected?
Narrow claims reveal the inventor’s preferred implementation. Working outside these ranges may avoid dependent claim infringement while maintaining primary claim exposure.
Examples
What are the validated quantitative formulation parameters? What dissolution or stability benchmarks were achieved?
Sets the performance target for your design-around. Your formulation must meet or exceed these benchmarks to support a bioequivalence argument.
Prosecution History
What arguments did the inventor make to overcome examiner rejections? What amendments were made to the claims?
Prosecution history estoppel limits the Doctrine of Equivalents scope. Elements abandoned during prosecution cannot be reclaimed as equivalents.
Phase 2: Identifying Design-Around Levers
After deconstructing the patent, identify the elements with the greatest design-around flexibility.
Excipient substitution works when the patent claims a specific excipient class or a specific compound within a class. The substitution candidate must be selected from the unclaimed disclosure, or from the general formulation science literature, and must not perform substantially the same function in substantially the same way as the claimed excipient. The Doctrine of Equivalents test, known as the function-way-result test, defines equivalence: same function, same way, same result means infringement. A different polymer that achieves the same dissolution profile through the same swelling mechanism is a high-risk substitute regardless of its chemical name.
Concentration shifts work when the patent claims a specific ratio or percentage range. Operating outside the claimed range is not independently sufficient to avoid infringement; the Doctrine of Equivalents may still apply if the shift produces no material change in product performance. But if the shift requires meaningful reformulation adjustments (different process parameters, different stability profile, different particle size specification), it supports an argument that the function or way is materially different.
Process modification works when the claim language ties the product to a specific manufacturing method (‘a pharmaceutical composition prepared by hot-melt extrusion’). Producing a bioequivalent product through spray drying or solvent granulation may avoid literal infringement of a process-dependent product claim, provided the resulting product’s physical characteristics (particle morphology, crystallinity, dissolution rate) are measurably different from those achievable by the patented process.
Phase 3: Doctrine of Equivalents Risk Assessment
Literal design-around is not final clearance. The Doctrine of Equivalents allows a patent holder to claim infringement by a product that does not literally satisfy every claim element, if the accused product contains an element that performs substantially the same function, in substantially the same way, to achieve substantially the same result.
The prosecution history estoppel doctrine limits this. If the patent applicant, during examination, surrendered claim scope to overcome a prior art rejection, the patent holder cannot later use the Doctrine of Equivalents to recapture that surrendered scope. Reading the full prosecution history (available through USPTO Patent Center) is required to assess estoppel scope before concluding that a literal design-around is safe.
This analysis is beyond the competence of pharmaceutical scientists working alone. Formulation scientists and patent counsel must work jointly: the scientist identifies the technically viable alternatives, and the attorney assesses which of those alternatives fall outside the Doctrine of Equivalents scope given the patent’s prosecution history. Neither analysis alone is sufficient.
Freedom-to-Operate Analysis: Procedure and Best Practices
What FTO Analysis Establishes and What It Does Not
An FTO analysis addresses one question: can the proposed product be manufactured, used, and sold in a defined jurisdiction without infringing an active, enforceable third-party patent? It does not address whether the product is patentable (a separate patentability analysis), whether it complies with FDA regulations (a regulatory review), or whether it infringes trade secrets or copyrights (separate IP analyses).
An FTO opinion letter from qualified patent counsel creates a documented, good-faith basis for the commercialization decision. If infringement litigation follows, a prior written FTO opinion from qualified counsel is admissible evidence relevant to the willfulness question. Willful infringement supports an award of enhanced (up to treble) damages under 35 U.S.C. § 284. An FTO opinion, even if the product is ultimately found to infringe, can establish that the infringement was not willful and limit damages exposure accordingly.
The Four-Phase FTO Process
Phase 1 — Scoping. Define the exact technical parameters of the product to be analyzed: API, salt form, polymorphic form, every excipient with concentration, dosage form, route of administration, manufacturing process, and packaging. Define every jurisdiction where the product will be manufactured, distributed, and sold. Imprecise scoping produces an FTO opinion that does not actually clear the intended product.
Phase 2 — Search Strategy Execution. The search must cover keyword, classification, assignee, and chemical structure queries across both USPTO and EPO databases, supplemented by commercial databases with global coverage. The search should include patents assigned to the brand manufacturer’s parent company, subsidiary companies, and any research institution that has licensed IP to the manufacturer, which are frequently not searched in a manufacturer-name-only approach.
Phase 3 — Claim Mapping and Risk Stratification. Each identified patent’s independent claims are mapped element-by-element to the proposed product’s parameters. Patents are stratified into risk tiers:
High risk: claims that are literally infringed by the proposed product in its current configuration, with no identified design-around modification available without compromising clinical performance.
Medium risk: claims where infringement depends on an unresolved claim construction question, where Doctrine of Equivalents exposure is present but estoppel arguments are available, or where a design-around modification is technically feasible but not yet validated.
Low risk: claims that are not literally infringed and for which Doctrine of Equivalents exposure is minimal given clear prosecution history estoppel or functional differences in the proposed formulation.
Phase 4 — Opinion and Recommendation. The FTO opinion should provide a clear product-specific risk assessment with a documented recommendation: proceed, proceed with identified design-around modifications, seek a license, or do not proceed. The opinion must identify the patents analyzed, the claim mapping methodology, and the legal reasoning underlying each risk assignment.
FTO analysis is not a static document. New patents issue continuously. Orange Book listings change. A product with a clean FTO today may face new exposure from a patent granted on a pending application that was published after the search date. Any compounding facility operating an active product development pipeline should maintain a monitoring program for newly published applications in their target drug categories and refresh FTO analysis on a defined schedule, typically annually for each product in commercial production.
Part 5: Litigation Exposure, Enforcement Reality, and the Forward Landscape
The Financial and Operational Reality of Patent Litigation
Patent infringement claims against compounders are not hypothetical. They are an active enforcement mechanism used by brand manufacturers to protect revenue at risk.
Patent litigation through trial in the pharmaceutical sector averaged approximately $3 million in 2023. This figure represents defense costs alone, excluding damages. If a compounder is found liable for infringement, the patent holder may elect to recover either lost profits (what the brand manufacturer lost on each sale the compounder made) or a reasonable royalty on each infringing unit sold. For a 503B facility that produced large volumes of a shortage drug for 18 months before an injunction, lost profits damages can reach figures that exceed the facility’s annual revenue.
A court may also issue a permanent injunction requiring immediate cessation of production and sale of the infringing product. An injunction is not a damages-in-lieu-of-cessation order. It is a court order to stop. Violation of an injunction is contempt of court.
Case Study: Bayer v. Wedgewood Village Pharmacy
Bayer Healthcare’s suit against Wedgewood Village Pharmacy, one of the largest compounding pharmacies in the United States, illustrates the target range of patent enforcement. Bayer manufactured Marquis, an FDA-approved drug for equine protozoal myeloencephalitis, and held a patent on the formulation. Wedgewood was compounding a version of the drug.
The suit resulted in a permanent injunction against Wedgewood. Industry observers noted that the case was likely motivated in part by Bayer’s frustration with FDA’s enforcement posture toward compounders producing copies of approved drugs, leading Bayer to use its own IP rights as a private enforcement mechanism. The lesson: brand manufacturers who cannot get the FDA to act will use their patent portfolios instead, and they have the resources to litigate aggressively.
The Multi-Claim Legal Strategy: Beyond Patent Infringement
Brand manufacturers in the compounding context rarely file single-claim suits. The standard litigation package includes:
Patent infringement under 35 U.S.C. § 271. This is the primary claim. It requires the manufacturer to show that the compounder’s product practices every element of at least one valid patent claim.
Trademark infringement under 15 U.S.C. § 1114. Using a registered trademark (Ozempic, Mounjaro, Wegovy, Zepbound) in advertising a compounded product, even with a disclaimer, is actionable. The legal standard for trademark infringement is likelihood of consumer confusion, not actual confusion. Marketing materials for compounded semaglutide that feature the Ozempic name are textbook trademark infringement regardless of whether the patent infringement claim succeeds.
False advertising under 15 U.S.C. § 1125(a). Claims that a compounded drug is ‘FDA-approved,’ ‘bioequivalent,’ or ‘the same as’ the branded drug are false. Compounded drugs are not approved drugs, and FDA approval is a legal status, not a quality descriptor.
State consumer protection claims. State-level unfair business practice statutes frequently provide additional causes of action parallel to federal trademark and false advertising claims, and may permit recovery of attorneys’ fees.
A compliance program for a compounding facility operating in the shortage or shortage-adjacent market must address all four categories, not just the patent exposure.
The Biologic Ceiling: Why 503A and 503B Cannot Compound PHS Act Biologics
The Statutory Prohibition
The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act in 2010 and effective March 23, 2020 for the compounding industry, established that biological products licensed under Section 351 of the Public Health Service Act are not eligible for the compounding exemptions under Sections 503A or 503B of the FD&C Act.
This is a categorical prohibition. It applies to monoclonal antibodies, therapeutic proteins, vaccines, blood and blood components, and other PHS Act-licensed biologics. It is not waived by a drug shortage designation. A 503A or 503B facility cannot compound adalimumab, pembrolizumab, trastuzumab, or any other PHS-licensed biologic from bulk drug substances, shortage or not.
The FDA has issued guidance permitting the mixing, diluting, or repackaging of already-approved sterile biologic products under defined conditions for patient-specific administration. This is a narrow operational permission for dose preparation, not a license to produce compounded biologic drug products from API.
The Technology Roadmap Implication for Compounders
The pharmaceutical industry’s pipeline is biologic-dominant. Oncology, autoimmune disease, rare disease, and neurology are all fields where monoclonal antibodies, antibody-drug conjugates, cell therapies, and gene therapies represent the primary innovation frontier. As small-molecule drugs age off patent and biologics represent a growing proportion of new approvals, the compounding industry’s addressable market within the 503A/503B framework will increasingly be limited to the small-molecule segment of the pharmaceutical market.
This is not a crisis for existing compounders whose business is concentrated in sterile small-molecule products (anti-infectives, analgesics, anesthetics, cardioplegia solutions, ophthalmics). It is a ceiling on the compounding industry’s growth trajectory relative to the pharmaceutical market as a whole. Compounding facilities evaluating long-term strategic positioning should model their revenue exposure to this ceiling and identify whether a meaningful portion of their formulation development pipeline includes molecules that may transition to PHS Act licensing at a future date.
The Regulatory Horizon: FDA Enforcement Trends and Patent Reform
FDA Enforcement Priorities
Following the NECC tragedy and the GLP-1 market disruption, FDA enforcement resources are concentrated on three areas relevant to compounders.
Bulk drug substance sourcing: the FDA requires that bulk APIs used in compounding be purchased from registered suppliers with current certificates of analysis. Enforcement actions for adulterated APIs sourced from unregistered foreign suppliers have increased in frequency. Any 503A or 503B facility that sources API from international bulk suppliers must conduct documented supplier qualification audits and maintain incoming material testing programs.
Online pharmacy and telehealth platform monitoring: the FDA’s digital health surveillance activity has increased substantially in the past 24 months. Platforms that market compounded drugs directly to consumers using brand names, before-and-after testimonials, or language implying FDA equivalence are active enforcement targets.
The proposed ‘Demonstrably Difficult to Compound’ list would prohibit compounding of drugs whose pharmacological, chemical, or physical characteristics make consistent quality at the compounder level unrealistic. This proposed category, if finalized, would add a product-specific compounding prohibition on top of the existing ‘essentially a copy’ prohibition, narrowing the scope of permissible compounding for a defined set of high-risk formulations.
Congressional and academic proposals for pharmaceutical patent reform are active, though legislative progress is slow. Two proposals are directly relevant to compounders.
Patent thicket reform: proposals include limiting the number of Orange Book-eligible patents per NDA, increasing USPTO examination standards for secondary patents, and mandating greater disclosure of inter-patent relationships. If any of these measures were enacted, they would reduce the patent density surrounding blockbuster drugs and potentially accelerate generic entry timelines, which would create more frequent LOE windows for compounders to evaluate.
A statutory compounding infringement exemption: legal scholars have proposed an explicit exemption from patent infringement liability for pharmacies compounding drugs during an active FDA-declared shortage. This would resolve the core legal paradox that currently makes shortage market entry a dual-risk proposition. The proposal faces substantial opposition from the innovator pharmaceutical industry, which argues that such an exemption would undermine the financial model that funds new drug development.
Neither reform is imminent. Compounders should track both through industry associations and legislative monitoring services, but should not incorporate either into current business planning.
Part 6: Operational Compliance Architecture for Compounder IP Teams
Building a Continuous Patent Monitoring Program
A compounding facility that operates a reactive patent monitoring approach, checking patent status when a product is proposed rather than continuously, will consistently lag the market. An effective program monitors:
Newly published USPTO patent applications in the relevant CPC classifications on a monthly cadence. Published applications become enforceable patents upon issuance, which typically occurs 18 to 30 months after publication. A monthly review of newly published applications by the brand manufacturer for any drug in the facility’s active product portfolio provides advance notice before a new patent creates exposure.
Orange Book listing changes for all drugs in the active portfolio. The FDA updates the Orange Book continuously. New patent listings, corrections, and deletions occur regularly. A change to the Orange Book for a drug in production is a trigger event requiring immediate FTO review.
Federal court filings by brand manufacturers against compounders. PACER (Public Access to Court Electronic Records) provides full access to federal court filings. Tracking new complaint filings by major brand manufacturers identifies enforcement activity in real time, reveals the legal theories being asserted, and provides advance notice of the manufacturer’s litigation posture before it reaches the facility.
FDA shortage list additions and removals. FDA maintains the shortage list at fda.gov/drugs/drug-safety-and-availability/drug-shortages. Automated alerts for additions and removals are available through the FDA’s email subscription service.
The Clinical Differentiation File: Building the Regulatory Defense in Real Time
Every product in a 503B facility’s portfolio that contains an API shared with an approved drug requires a maintained clinical differentiation file. The file should contain:
The specific clinical difference identified for the compounded product relative to the approved drug (dosage strength, dosage form, excipient profile, or route of administration).
Practitioner statements for each non-patient-specific customer relationship, documenting the clinical difference and the patient population for which it applies.
Supporting clinical literature establishing the basis for the claimed clinical difference, where available.
A dated review history documenting when the clinical differentiation rationale was last evaluated against the current approved drug market (particularly relevant if the brand manufacturer launches a new approved formulation that might reduce the clinical differentiation argument).
This file is not a one-time document. It requires active maintenance because the approved drug market changes. A brand manufacturer that launches a new approved formulation in the strength range previously only available through compounding eliminates the clinical differentiation argument for that product.
For institutional investors, M&A analysts, and lenders evaluating compounding sector operators, the following factors drive the gap between book value and strategic value:
Product concentration risk: a facility whose revenue is greater than 40% concentrated in shortage-derived products carries material binary risk. The shortage designation could be lifted, the patent holder could obtain an injunction, or both. LOE-based product diversification is the primary hedge.
IP asset capture: a 503B facility with a portfolio of proprietary compounded formulations that it has evaluated for patentability, and has filed provisional applications where warranted, holds identifiable IP assets. These assets are not reflected in standard pharmacy EBITDA multiples but represent durable competitive protection.
Litigation history and pending exposure: any compounding facility with settled or pending patent, trademark, or false advertising litigation should be valued with a full disclosure-based analysis of the claimed damages, the settlement terms, and the injunctive relief exposure in any ongoing matter.
CGMP audit record: for 503B facilities, the FDA inspection history (available through FDA Establishment Inspection Reports, obtained via FOIA request) is a proxy for CGMP quality system maturity. Warning letters, Form 483 observations, and consent decree history are material to revenue durability assessments because CGMP failure events can result in mandatory production shutdowns with immediate revenue consequences.
Frequently Asked Questions
Q: If a drug is on the FDA shortage list, am I protected from a patent lawsuit?
No. The FDA shortage designation is a provision of the FD&C Act that suspends the ‘essentially a copy’ prohibition for compounders. It has no effect on the Patent Act. A brand manufacturer with valid patents on a shortage-listed drug retains full patent enforcement rights during the shortage period. FDA permission to compound and patent infringement exposure exist simultaneously and independently. Any compounder entering a shortage market must conduct FTO analysis covering the patent landscape, not just confirm the shortage listing.
Q: How much documentation is required to support a ‘significant difference’ claim for a 503A prescription?
The documentation must be explicit, contemporaneous, and clinically specific. General notations like ‘medically necessary’ are insufficient. The prescribing practitioner’s documentation should identify both the specific modification (liquid formulation, dye-free preparation, altered strength) and the patient-specific clinical reason (dysphagia, documented allergy to the dye, intolerance to standard strength). This language must appear on the prescription or in an attached, signed document at the time of dispensing. The dispensing pharmacist bears the burden of ensuring the documentation is adequate.
Q: Does changing one excipient automatically avoid formulation patent infringement?
No. Excipient substitution avoids literal infringement of a claim element only if the substituted excipient is not recited in the claim. If the substituted excipient performs substantially the same function, in substantially the same way, to achieve substantially the same result as the claimed excipient, infringement under the Doctrine of Equivalents is still possible. The prosecution history of the patent must be reviewed to determine whether the patent holder is estopped from asserting equivalence for that excipient substitution. This is a legal analysis requiring patent counsel, not a formulation decision that can be made unilaterally by a pharmaceutical scientist.
Q: What is the most common mistake compounders make when reviewing drug patents?
Focusing on the primary composition-of-matter patent expiration date and treating it as the end of the exclusivity period. Composition-of-matter patents on APIs are generally the first to expire, not the last. The formulation, polymorph, method-of-use, and delivery device patents that are filed years after the NDA approval are frequently the relevant barriers at the time a compounder is evaluating product development. The Orange Book lists all patents the manufacturer has chosen to assert; additional non-listed patents covering process and packaging must be identified through an independent USPTO assignee search.
Q: Why cannot a 503B facility compound a biologic like pembrolizumab (Keytruda) even if it is in shortage?
Pembrolizumab is licensed as a biological product under Section 351 of the Public Health Service Act, not as a drug under the FD&C Act. As of March 23, 2020, PHS Act-licensed biologics are explicitly excluded from the compounding exemptions provided by Sections 503A and 503B of the FD&C Act. The drug shortage exception does not override this categorical exclusion. The FDA has issued guidance permitting limited mixing, diluting, and repackaging of approved sterile biologics for patient-specific dose preparation, but this is distinct from compounding a biologic from bulk drug substances.
Q: How frequently should an FTO analysis be updated?
An FTO analysis should be treated as a living document, not a one-time clearance exercise. For any product in commercial production, the FTO should be reviewed: (1) annually as a standard schedule, (2) immediately when a new patent is published by the brand manufacturer in the relevant drug class, (3) when an Orange Book listing change adds a new patent to the reference drug’s IP registry, and (4) when a generic Paragraph IV filing challenges or settles a patent previously identified as high-risk in the FTO. A patent granted after the FTO was conducted can create new infringement exposure retroactively from its issuance date.
This analysis is intended for informational purposes for pharma/biotech IP teams, portfolio managers, and R&D leads. It does not constitute legal advice. Specific patent infringement and FTO questions require consultation with qualified patent counsel.
